Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

Key Takeaways Cabometyx is now FDA-approved for previously treated pancreatic and extra-pancreatic NET. Early demand is strong, with 35% new patient share for oral therapies in this indication. Shares of Exelixis are up 13.8% YTD, though valuation remains above industry averages. Exelixis’ ((EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), is one of the leading drugs for the treatment of renal cell carcinoma (RCC).The FDA approval for the label expansion of Cabometyx for the treatment of adult ...